Skip to main content

Table 3 Dossier evidence use according to evidence characteristics

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

  Total included studies Used qualitatively Used in MA Fills a gap Confirms findings Changes conclusion
All dossier evidence 160 142 (89%) 26 (16%) 72 (45%) 66 (41%) 67 (42%)
Unique studies 123 105 (85%) 24 (20%) 57 (46%) 47 (38%) 56 (46%)
Supplemental evidence 37 36 (97%) 2 (5%) 15 (41%) 19 (51%) 9 (24%)
By study design
 Head to head trial 41 32 (78%) 9 (22%) 18 (44%) 15 (37%) 21 (13%)
 Placebo-controlled trial 46 39 (85%) 10 (22%) 23 (50%) 21 (46%) 21 (46%)
 Observational study 28 27 (96%) 0 13 (46%) 5 (18%) 9 (32%)
Publication status
 Published (all) 95 81 (85%) 18 (19%) 43 (45%) 43 (45%) 37 (39%)
 Unpublished (all) 65 58 (89%) 8 (12%) 29 (45%) 23 (35%) 29 (45%)
 Unpublished unique studies 46 39 (85%) 8 (17%) 22 (48%) 14 (30%) 25 (54%)
 Unpublished supplemental 19 19 (100%) 0 7 (37%) 9 (47%) 4 (21%)
 Subgroup evidence 26 25 (96%) 3 (12%) 15 (58%) 9 (35%) 12 (46%)
DERP phase
 DERP II 68 62 (91%) 13 (19%) 22 (32%) 32 (47%) 16 (24%)
 DERP III 50 44 (88%) 7 (14%) 28 (56%) 19 (38%) 29 (58%)
 DERP IV 42 35 (83%) 6 (14%) 22 (52%) 15 (36%) 21 (50%)
Publication status by DERP phase
 Published 95      
 DERP II 55 50 (91%) 9 (16%) 21 (38%) 24 (44%) 15 (27%)
 DERP III 17 14 (82%) 3 (18%) 8 (47%) 9 (53%) 7 (41%)
 DERP IV 23 17 (74%) 6 (26%) 14 (61%) 10 (43%) 15 (65%)
Unpublished 65      
 DERP II 13 9 (69%) 4 (31%) 1 (8%) 8 (62%) 1 (8%)
 DERP III 33 30 (91%) 4 (12%) 20 (61%) 10 (30%) 22 (67%)
 DERP IV 19 19 (100%) 0 8 (42%) 5 (26%) 6 (32%)
Report type 160      
 Original 48 39 (81%) 15 (31%) 19 (40%) 29 (60%) 23 (48%)
 Update 112 100 (89%) 11 (10%) 53 (47%) 37 (33%) 43 (38%)